2020
JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaJAK inhibitionCTCL cellsMalignant cutaneous T-cell lymphomasAdvanced cutaneous T-cell lymphomaTreatment of CTCLAvailable systemic treatment optionsSkin-homing T lymphocytesSystemic treatment optionsT-cell lymphomaCTCL cell linesHistone deacetylase inhibitionGeneralized cytotoxic effectExpression of Bcl2Advanced diseaseSuch patientsPeripheral bloodTreatment optionsJAK/STAT pathwayT lymphocytesPreclinical assessmentTherapeutic targetStrong potentiationExtrinsic apoptosis pathwayDeacetylase inhibitionInsights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
Yumeen S, Girardi M. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma. The Yale Journal Of Biology And Medicine 2020, 93: 111-121. PMID: 32226341, PMCID: PMC7087059.Peer-Reviewed Original ResearchConceptsGenomic copy number alterationsSingle nucleotide variantsCutaneous T-cell lymphomaCellular underpinningsJAK-STAT activationT-cell lymphomaT lymphocytesCopy number alterationsCTCL cellsSeries of alterationsWhole-exome sequencingCell lymphomaApoptosis resistanceNucleotide variantsOncogenic behaviorPathophysiology of CTCLSkin-homing T lymphocytesT cell activationCell expansionNumber alterationsCTCL pathogenesisGenetic alterationsGenomic alterationsCell-mediated immunityTherapeutic discovery
2008
Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities.
Berger CL, Heald P, Girardi M, Edelson RL. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. Giornale Italiano Di Dermatologia E Venereologia 2008, 143: 43-54. PMID: 18833050.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAnimalsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsApoptosisBexaroteneClone CellsCytokinesDendritic CellsDiphtheria ToxinGene Expression Regulation, NeoplasticHumansImmunophenotypingInterleukin-2Lymphoma, T-Cell, CutaneousMiceNeoplastic Stem CellsPhotopheresisPUVA TherapyRecombinant Fusion ProteinsTetrahydronaphthalenesT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryConceptsCutaneous T-cell lymphomaSheep red blood cellsT-cell lymphomaNew therapeutic approachesBasic science techniquesRed blood cellsClinical featuresTherapeutic optionsT lymphocytesCell lymphomaTherapeutic approachesClinical practiceImmune systemMalignant cellsTherapeutic opportunitiesBlood cellsPatientsImmunobiologyDiseaseMolecular demonstrationCurrent understandingCellsLymphomaLymphocytesImmunologyConventional and Unconventional T Cells
Roberts S, Girardi M. Conventional and Unconventional T Cells. 2008, 85-104. DOI: 10.1007/978-1-84800-165-7_6.Peer-Reviewed Original ResearchUnconventional T cellsConventional T cellsT cellsT cell receptorInvariant natural killer T (iNKT) cellsNatural killer T cellsContext of CD1dKiller T cellsNatural killer cellsNKT cellsLymph nodesKiller cellsPeripheral bloodGenitourinary tractInflammatory responseT lymphocytesGastrointestinal tractFunctional capacityCo-receptors CD4Host defenseCell receptorCancer cellsEpithelial environmentLymphocytesInfection